Fx-1006A
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transthyretin-associated Amyloidosis With Polyneuropathy
Conditions
Transthyretin-associated Amyloidosis With Polyneuropathy
Trial Timeline
Jun 1, 2008 → Jan 1, 2010
NCT ID
NCT00630864About Fx-1006A
Fx-1006A is a phase 2 stage product being developed by Pfizer for Transthyretin-associated Amyloidosis With Polyneuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT00630864. Target conditions include Transthyretin-associated Amyloidosis With Polyneuropathy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00694161 | Phase 2 | Completed |
| NCT00791492 | Phase 2/3 | Completed |
| NCT00630864 | Phase 2 | Completed |